Literature DB >> 2666667

Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol.

J G Berger1, W K Chang, J W Clader, D Hou, R E Chipkin, A T McPhail.   

Abstract

The synthesis of a structurally novel series of 6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphtho[2,1-b]azepines (2), conformationally restricted analogues of the dopamine D1 antagonist (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin -7-ol (SCH 23390, 1c), is described. Affinity for D1 receptors was determined by competition for rat striatal binding sites labeled by [3H]SCH 23390; affinity for D2 receptors was similarly determined by competition experiments using [3H]spiperone. Compounds in this series having the B/C-trans ring junction (2b and related analogues), where the D ring is unequivocally fixed in an equatorial orientation, possess considerably more D1 receptor affinity and selectivity vs the D2 receptor than the conformationally mobile cis stereoisomers (2a), thus leading to the conclusion that axial substituents at the 4- or 5-positions of the benzazepine nucleus are detrimental to D1 receptor affinity. Resolution and X-ray analysis demonstrated that D1 receptor affinity was preferentially associated with the (-)-6aS,13bR enantiomer of 2b.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2666667     DOI: 10.1021/jm00128a038

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  (18)F-Fluorodeoxyglucamines: Reductive amination of hydrophilic (18)F-fluoro-2-deoxyglucose with lipophilic amines for the development of potential PET imaging agents.

Authors:  Aparna Baranwal; Jogeshwar Mukherjee
Journal:  Bioorg Med Chem Lett       Date:  2015-05-29       Impact factor: 2.823

2.  Synthesis, pharmacological evaluations, and molecular docking studies on a new 1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine framework: Rigidification of D1 receptor selective 1-phenylbenzazepines and discovery of a new 5-HT6 receptor scaffold.

Authors:  Rajan Giri; Ian Alberts; Wayne W Harding
Journal:  Chem Biol Drug Des       Date:  2020-04-22       Impact factor: 2.817

3.  Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

Authors:  Alia H Clark; John D McCorvy; Val J Watts; David E Nichols
Journal:  Bioorg Med Chem       Date:  2011-08-03       Impact factor: 3.641

4.  Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man.

Authors:  P Karlsson; G Sedvall; C Halldin; C G Swahn; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 5.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.